First in vivo gene-editing drugs enter the clinic

The FDA posted strong approval numbers last year, rebounding from a steep drop in 2016. The agency’s Center for Drug Evaluation and Research (CDER) approved a total of 46 new drugs in 2017, the most since the peak of 59 in 1996 (FIG. 1; TABLE 1). This puts last year’s approval count well above the 5-year and 10-year averages (36 and 32, respectively)…

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE REVIEWS | DRUG DISCOVERY ADVANCE ONLINE PUBLICATION | 1